INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

NCT03491683 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

BIOLOGICAL: INO-5401
BIOLOGICAL: INO-9012
BIOLOGICAL: Cemiplimab
RADIATION: Radiation Therapy
DRUG: Temozolomide

Sponsor

Inovio Pharmaceuticals